Radiology, Vol 198, 327-332, Copyright © 1996 by Radiological Society of North America

ARTICLES

Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy

MA Helvie, LK Joynt, RL Cody, LJ Pierce, DD Adler and SD Merajver
Department of Radiology, University of Michigan Medical Center, Ann Arbor 48109-0326, USA.

PURPOSE: To determine the mammographic features of locally advanced breast carcinoma treated with neoadjuvant chemotherapy and to evaluate the accuracy of mammography in the prediction of residual carcinoma. MATERIALS AND METHODS: Of 90 women treated with hormonally synchronized cytotoxic therapy before mastectomy or lumpectomy for advanced breast carcinoma, 56 were selected because they had undergone mammography before and after neo-adjuvant therapy. Mammographic and clinical opinion on the presence of residual disease was compared with histologic results. RESULTS: Fifty-four (96%) of 56 women had a complete (n = 34 [61%]) or partial (n = 20 [36%]) clinical response. Thirteen (23%) of 56 women had no residual tumor. Sensitivity of mammography in the prediction of residual carcinoma was greater than that of clinical examination (79% vs 49%), but specificity was lower (77% vs 92%). In 24 women with inflammatory carcinoma, sensitivity of mammography was 78% while that of clinical examination was 39%; specificity was equal (83%). CONCLUSION: Mammography was more sensitive than clinical examination in the prediction of residual carcinoma; it was not accurate enough to obviate surgical biopsy.

This article has been cited by other articles:

				S. Orel Who Should Have Breast Magnetic Resonance Imaging Evaluation? J. Clin. Oncol., February 10, 2008; 26(5): 703 - 711. [Abstract] [Full Text] [PDF]

				D. J. Hsiang, M. Yamamoto, R. S. Mehta, M.-Y. Su, C. H. Baick, K. T. Lane, and J. A. Butler Predicting Nodal Status Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy With and Without Sequential Trastuzumab Arch Surg, September 1, 2007; 142(9): 855 - 861. [Abstract] [Full Text] [PDF]

				A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy PNAS, March 6, 2007; 104(10): 4014 - 4019. [Abstract] [Full Text] [PDF]

				F. Peintinger, H. M. Kuerer, K. Anderson, J. C. Boughey, F. Meric-Bernstam, S. E. Singletary, K. K. Hunt, G. J. Whitman, T. Stephens, A. U. Buzdar, et al. Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy Ann. Surg. Oncol., November 1, 2006; 13(11): 1443 - 1449. [Abstract] [Full Text] [PDF]

				I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]

				M. A. Roubidoux, G. L. LeCarpentier, J. B. Fowlkes, B. Bartz, D. Pai, S. P. Gordon, A. F. Schott, T. D. Johnson, and P. L. Carson Sonographic Evaluation of Early-Stage Breast Cancers That Undergo Neoadjuvant Chemotherapy J. Ultrasound Med., July 1, 2005; 24(7): 885 - 895. [Abstract] [Full Text] [PDF]

				N. E. Davidson and M. Morrow Sometimes a Great Notion--An Assessment of Neoadjuvant Systemic Therapy for Breast Cancer J Natl Cancer Inst, February 2, 2005; 97(3): 159 - 161. [Full Text] [PDF]

				E. Thomas, F. A. Holmes, T. L. Smith, A. U. Buzdar, D. K. Frye, G. Fraschini, S. E. Singletary, R. L. Theriault, M. D. McNeese, F. Ames, et al. The Use of Alternate, Non-Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial J. Clin. Oncol., June 15, 2004; 22(12): 2294 - 2302. [Abstract] [Full Text] [PDF]

				J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902 J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237. [Abstract] [Full Text]

				W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]

				T. Nakamura, T. Fukutomi, H. Tsuda, S. Akashi-Tanaka, K. Matsuo, C. Shimizu, and K. Miyakawa Changes in Findings of Mammography, Ultrasonography and Contrast-enhanced Computed Tomography of Three Histological Complete Responders with Primary Breast Cancer Before and After Neoadjuvant Chemotherapy: Case Reports Jpn. J. Clin. Oncol., October 1, 2000; 30(10): 453 - 457. [Abstract] [Full Text] [PDF]

				M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]